Key result
Second-generation antipsychotics increased body mass index from baseline at 6 months in both youth and adult SGA-naïve patients.
Why the study?
Do second-generation antipsychotics cause age-dependent metabolic changes in SGA-naïve patients?
Cohort (n=85)
Do second-generation antipsychotics cause age-dependent metabolic changes in SGA-naïve patients?
Second-generation antipsychotics induce significant weight gain in both youths and adults, but adverse lipid changes were only observed in adults within the first 6 months.
Answers are grounded in this paper and cite their sources.
SGA use was associated with substantial BMI gains in SGA-naïve patients regardless of age; leaves open age-specific lipid effects for prospective study.
BACKGROUND: Patients receiving second-generation antipsychotics (SGAs) may experience secondary metabolic effects such as weight gain, as well as changes in lipid and glucose metabolism. These effects are well documented in adults; however, fewer studies are available concerning their occurrence and their evolution in children and adolescents. OBJECTIVE: The aim of this study was to determine if there is an age-dependent variation in the metabolic effects of SGAs in a drug-naïve population. METHODS: Charts of 232 French Canadian patients participating in a program monitoring the metabolic effects of SGAs were retrospectively reviewed. A total of 85 SGA-naïve patients were selected, including 58 youths and 27 adults. Changes, relative to baseline, in weight, body mass index, lipid metabolism (total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglyceride), and fasting blood glucose were assessed, with follow-up at 3, 6, 12, and 24 months. RESULTS: With respect to weight gain, in both the youth and adult groups, body mass index significantly increased from baseline at 3 months (10.1% [p < 0.0001] and 12.2% [p < 0.0001], respectively) and 6 months (11.8% [p < 0.0001] and 13.1% [p < 0.0001], respectively). With respect to lipid metabolism, in the youth group, there was no significant change. In the adult group, there was a significant increase at 3 and 6 months in total cholesterol (24.0% [p = 0.004] and 24.1% [p = 0.0006], respectively), low-density lipoprotein (26.8% [p = 0.019] and 30.1% [p = 0.010], respectively), and high-density lipoprotein (10.2% [p = 0.04] and 17.1% [p = 0.005], respectively). There was no significant change in triglyceride and glucose metabolism in both groups. CONCLUSIONS: Our results confirm the age-independent effects of SGA on weight gain. However, more data are needed to explore the age effect on glucose and lipid metabolism.
No takes yet. Share an insight, caveat, or question.
Roy et al. (2010) conducted a cohort in Patients receiving second-generation antipsychotics (n=85). Second-generation antipsychotics vs. Baseline was evaluated on Change in body mass index from baseline at 6 months (p=<0.0001). Second-generation antipsychotics increased body mass index from baseline at 6 months in both youth and adult SGA-naïve patients.
Synapse has enriched 10 related papers. Consider them for comparative context: